Thomas A. Gerken

Thomas A. Gerken

Auto-generated profile, based on publicly available information

Thomas A. Gerken

Case Western Reserve University

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
TGThomas A. Gerken
Thomas A. Gerken
OJOliver Jamison
Oliver Jamison
CPCynthia L. Perrine
Cynthia L. Perrine
JCJeremy C. Collette
Jeremy C. Collette
HMHelen Moinova
Helen Moinova
LTLawrence A. Tabak
Lawrence A. Tabak
Mammalian mucin-type O-glycosylation is initiated by a large family of ∼20 UDP-GalNAc:polypeptide α-N-acetylgalactosaminyltransferases (ppGalNAc Ts) that transfer α-GalNAc from UDP-GalNAc to Ser and Thr residues of polypeptide acceptors. Characterizing the peptide substrate specificity of each isoform is critical to understanding their properties, biological roles, and significance. Presently, only the specificities of ppGalNAc T1, T2, and T10 and the fly orthologues of T1 and T2 have been systematically characterized utilizing random peptide substrates. We now extend these studies to ppGalNAc T3, T5, and T12, transferases variously associated with human disease. Our results reveal several common features; the most striking is the similar pattern of enhancements for the three residues C-terminal to the site of glycosylation for those transferases that contain a common conserved Trp. In contrast, residues N-terminal to the site of glycosylation show a wide range of isoform-specific enhancements, with elevated preferences for Pro, Val, and Tyr being the most common at the −1 position. Further analysis reveals that the ratio of positive (Arg, Lys, and His) to negative (Asp and Glu) charged residue enhancements varied among transferases, thus further modulating substrate preference in an isoform-specific manner. By utilizing the obtained transferase-specific preferences, the glycosylation patterns of the ppGalNAc Ts against a series of peptide substrates could roughly be reproduced, demonstrating the potential for predicting isoform-specific glycosylation. We conclude that each ppGalNAc T isoform may be uniquely sensitive to peptide sequence and overall charge, which together dictates the substrate sites that will be glycosylated.

4 August 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
KGKishore Guda
Kishore Guda
HMHelen Moinova
Helen Moinova
JHJian He
Jian He
OJOliver Jamison
Oliver Jamison
LRLakshmeswari Ravi
Lakshmeswari Ravi
SMSanford D. Markowitz
Sanford D. Markowitz
Aberrant glycosylation is a pathological alteration that is widespread in colon cancer, and usually accompanies the onset and progression of the disease. To date, the molecular mechanisms underlying aberrant glycosylation remain largely unknown. In this study, we identify somatic and germ-line mutations in the gene encoding for polypeptide N -acetylgalactosaminyltransferase 12 ( GALNT12 ) in individuals with colon cancer. Biochemical analyses demonstrate that each of the 8 GALNT12 mutations identified inactivates the normal function of the GALNT enzyme in initiating mucin type O-linked protein glycosylation. Two of these inactivating GALNT12 mutations were identified as acquired somatic mutations in a set of 30 microsatellite stable colon tumors. Relative to background gene mutation rates, finding these somatic GALNT12 mutations was statistically significant at P < 0.001. Six additional inactivating GALNT12 mutations were detected as germ-line changes carried by patients with colon cancer; however, no inactivating variants were detected among cancer-free controls ( P = 0.005). Notably, in 3 of the 6 individuals harboring inactivating germ-line GALNT12 mutations, both a colon cancer and a second independent epithelial cancer had developed. These findings suggest that genetic defects in the O-glycosylation pathway in part underlie aberrant glycosylation in colon cancers, and they contribute to the development of a subset of these malignancies.

1 June 2019 in Current Opinion in Structural Biology
Verified
Journal Article
Closed access
MRMatilde de Las Rivas
Matilde de Las Rivas
ELErandi Lira-Navarrete
Erandi Lira-Navarrete
TGThomas A. Gerken
Thomas A. Gerken
RHRamón Hurtado-Guerrero
Ramón Hurtado-Guerrero

26 November 2015 in Glycobiology
Verified
Journal Article
Open access
PDF file
LRLeslie Revoredo
Leslie Revoredo
SWShengjun Wang
Shengjun Wang
EBEric Paul Bennett
Eric Paul Bennett
HCHenrik Clausen
Henrik Clausen
KMKelley W Moremen
Kelley W Moremen
TGThomas A Gerken
Thomas A Gerken
A large family of UDP-GalNAc:polypeptide GalNAc transferases (ppGalNAc-Ts) initiates and defines sites of mucin-type Ser/Thr-O-GalNAc glycosylation. Family members have been classified into peptide- and glycopeptide-preferring subfamilies, although both families possess variable activities against glycopeptide substrates. All but one isoform contains a C-terminal carbohydrate-binding lectin domain whose roles in modulating glycopeptide specificity is just being understood. We have previously shown for several peptide-preferring isoforms that the presence of a remote Thr-O-GalNAc, 6–17 residues from a Ser/Thr acceptor site, may enhance overall catalytic activity in an N- or C-terminal direction. This enhancement varies with isoform and is attributed to Thr-O-GalNAc interactions at the lectin domain. We now report on the glycopeptide substrate utilization of a series of glycopeptide (human-ppGalNAc-T4, T7, T10, T12 and fly PGANT7) and peptide-preferring transferases (T2, T3 and T5) by exploiting a series of random glycopeptide substrates designed to probe the functions of their catalytic and lectin domains. Glycosylation was observed at the −3, −1 and +1 residues relative to a neighboring Thr-O-GalNAc, depending on isoform, which we attribute to specific Thr-O-GalNAc binding at the catalytic domain. Additionally, these glycopeptide-preferring isoforms show remote lectin domain-assisted Thr-O-GalNAc enhancements that vary from modest to none. We conclude that the glycopeptide specificity of the glycopeptide-preferring isoforms predominantly resides in their catalytic domain but may be further modulated by remote lectin domain interactions. These studies further demonstrate that both domains of the ppGalNAc-Ts have specialized and unique functions that work in concert to control and order mucin-type O-glycosylation.

1 July 2013 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
TGThomas A. Gerken
Thomas A. Gerken
LRLeslie Revoredo
Leslie Revoredo
JTJoseph J. C. Thome
Joseph J. C. Thome
LTLawrence A. Tabak
Lawrence A. Tabak
MVMalene Bech Vester-Christensen
Malene Bech Vester-Christensen
KMKelley Moremen
Kelley Moremen
Mucin type O-glycosylation is initiated by a large family of polypeptide GalNAc transferases (ppGalNAc Ts) that add α-GalNAc to the Ser and Thr residues of peptides. Of the 20 human isoforms, all but one are composed of two globular domains linked by a short flexible linker: a catalytic domain and a ricin-like lectin carbohydrate binding domain. Presently, the roles of the catalytic and lectin domains in peptide and glycopeptide recognition and specificity remain unclear. To systematically study the role of the lectin domain in ppGalNAc T glycopeptide substrate utilization, we have developed a series of novel random glycopeptide substrates containing a single GalNAc-O-Thr residue placed near either the N or C terminus of the glycopeptide substrate. Our results reveal that the presence and N- or C-terminal placement of the GalNAc-O-Thr can be important determinants of overall catalytic activity and specificity that differ between transferase isoforms. For example, ppGalNAc T1, T2, and T14 prefer C-terminally placed GalNAc-O-Thr, whereas ppGalNAc T3 and T6 prefer N-terminally placed GalNAc-O-Thr. Several transferase isoforms, ppGalNAc T5, T13, and T16, display equally enhanced N- or C-terminal activities relative to the nonglycosylated control peptides. This N- and/or C-terminal selectivity is presumably due to weak glycopeptide binding to the lectin domain, whose orientation relative to the catalytic domain is dynamic and isoform-dependent. Such N- or C-terminal glycopeptide selectivity provides an additional level of control or fidelity for the O-glycosylation of biologically significant sites and suggests that O-glycosylation may in some instances be exquisitely controlled.

13 January 2020 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
MRMatilde de Las Rivas
Matilde de Las Rivas
EDEarnest James Paul Daniel
Earnest James Paul Daniel
YNYoshiki Narimatsu
Yoshiki Narimatsu
ICIsmael Compañón
Ismael Compañón
Kentaro KatoKentaro Kato
Kentaro Kato
RHRamón Hurtado-Guerrero
Ramón Hurtado-Guerrero